IBD Treatment: How New Research is Changing the Game
"Comparing Vedolizumab and Infliximab, and the Power of Patient Decision Aids"
Inflammatory Bowel Disease (IBD) is a chronic condition affecting millions, and finding the right treatment approach can feel like navigating a maze. Traditionally, treatment decisions have often been driven by physician preferences and standard protocols. However, new research is shedding light on the comparative effectiveness of different therapies and the importance of patient involvement in the decision-making process.
Two key studies presented at a recent European Crohn's and Colitis Organisation (ECCO) congress offer valuable insights. The first study compares the outcomes of vedolizumab (VDZ) and infliximab (IFX) as initial therapies for IBD. The second explores the impact of a Crohn's disease decision aid on treatment choices. Both studies highlight the evolving landscape of IBD management and the increasing focus on personalized care.
This article will delve into these studies, breaking down the key findings and explaining what they mean for individuals living with IBD. We'll explore the comparative effectiveness of VDZ and IFX, and examine how decision aids can empower patients to take an active role in their treatment journey. Our goal is to provide you with a clear understanding of these advancements, enabling you to have more informed conversations with your healthcare providers.
Vedolizumab vs. Infliximab: A Head-to-Head Comparison
One of the presented studies directly compared vedolizumab (VDZ) and infliximab (IFX) as initial treatments for IBD in biologic-naïve patients (those who had not previously used biologic therapies). This is significant because current guidelines often recommend VDZ after a patient has failed or become intolerant to a TNF antagonist like IFX. The study aimed to assess whether VDZ could be a viable first-line option.
- Treatment Discontinuation: How long patients stayed on each medication.
- Flare Rates: The frequency of disease flares requiring intravenous steroids.
- Hospitalization Rates: The number of all-cause hospitalizations.
- IBD-Related Surgeries: The number of surgeries related to IBD.
Vedolizumab Research in Practice
A 2020 review notes that newer biologic therapies have been designed to target the gut, with the aim of minimizing side effects and increasing responsiveness. A study published July 1, 2025, set out to assess vedolizumab’s real-life effectiveness and safety in a large IBD cohort and use machine learning to identify relevant outcome predictors. A separate August 2025 review focuses on the effectiveness, safety, and treatment compliance of subcutaneous vedolizumab in clinical practice for Crohn’s disease or ulcerative colitis.
Evidence Gaps and Unresolved Questions
A systematic review reports that no head-to-head randomized controlled trials have compared infliximab with vedolizumab for IBD, and that real-world comparisons are difficult to interpret without complementary trial evidence. In Crohn’s disease, the CALM and STARDUST trials evaluated treat-to-target approaches with adalimumab and ustekinumab, respectively. The practical guide concludes that it remains unclear which patient and disease characteristics are most likely to benefit from a treat-to-target approach.
Persistence in a German Registry
A pooled analysis of the prospective UMBRELLA-IBD Registry in Germany compared real-world treatment persistence in Crohn’s disease over 24 months. Persistence differed significantly across treatments (log-rank p < 0.001): it was highest for adalimumab at 81.4%, lowest for infliximab at 66.6%, and intermediate for ustekinumab at 78.6% and vedolizumab at 76.9%. These figures describe the registry analysis and do not establish a universal treatment ranking.
Empowering Patients Through Informed Choices
The research presented underscores a significant shift in IBD management: a move toward more personalized and patient-centered care. While the VDZ vs. IFX study provides valuable data on comparative effectiveness, the decision aid study highlights the crucial role of patient involvement.
Long-Term Data and Changing Formulations
A narrative review published May 25, 2026, describes recent advances in IBD treatment with a focus on vedolizumab, which it identifies as the first and only anti-lymphocyte trafficking agent approved as a gut-selective biologic for induction and maintenance therapy in IBD. Another listed research item is titled “Su1577 REAL-WORLD TRENDS IN SUBCUTANEOUS AND INTRAVENOUS INFLIXIMAB AND VEDOLIZUMAB USE IN INFLAMMATORY BOWEL DISEASE FROM 2021 TO 2024.” Its title identifies the drugs, routes, period, and Crohn’s Colitis Cure Data Insights Program, but the provided material does not report the trend results.
Treatment Experience Beyond Trials
The RALEE study was a retrospective observational study using claims data for patients with ulcerative colitis treated with vedolizumab from January 1, 2016, through December 31, 2019. In a separate real-world cohort of IBD patients who switched from intravenous to subcutaneous vedolizumab, with 18 months of follow-up, three out of four remained on subcutaneous treatment. Higher disease activity and preference for intravenous administration at the time of switching were associated with reduced drug persistence.
By providing patients with clear, unbiased information about treatment options and potential risks, decision aids empower them to have more informed conversations with their doctors and make choices that align with their individual values and preferences. This collaborative approach can lead to greater treatment adherence and improved outcomes.
Ultimately, the future of IBD treatment lies in combining the latest scientific evidence with a strong emphasis on patient empowerment. As research continues to refine our understanding of these complex conditions, tools like decision aids will play an increasingly vital role in helping patients navigate their treatment journey and achieve optimal health.